Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREEN MEMORY Phase 3 trial of sodium oligomannate in mild to moderate Alzheimer's disease
NL-OMON51880Phase 3Active, not recruiting
- Sponsor
- Green Valley
- Start
- Sep 2021
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing GV-971 with Placebo (2 arms). Primary endpoints: Change from baseline to end of double-blind study in ADAS-cog/11 and ADCS-CGIC at end of double-blind study. Started Sep 2021; status: active, not recruiting.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON51880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51880.